2024 PARTNERS

Lead Partner

BSP Pharmaceuticals

BSP Pharmaceuticals S.p. A. is focused on the development and manufacturing of anticancer drugs with high potency and cytotoxic characteristics for the Pharmaceuticals Industry. BSP has been at the forefront in the fight against cancer since 2006. Innovation is the hallmark of BSP with investments in new technologies and production methods in a high containment plant.

www.bsppharmaceuticals.com

Senior Partners

Ambrx - Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com or at www.janssen.com/johnson-johnson-innovative-medicine

Ajinomoto BioPharma Services

Ajinomoto Bio-Pharma Services offers comprehensive capabilities for small molecule APIs and biologics production, from process development and cGMP manufacturing to aseptic fill finish, including cytotoxics. As a global CDMO, they provide the adaptive solutions, responsive service, trusted partnership and peace of mind you’ve come to rely on.

www.ajibio-pharma.com

MilliporeSigma

MilliporeSigma is a leading Life Science company, providing solutions as a strategic partner to help advance the promise of life-saving therapies. Our integrated CTDMO Services combine our expertise in contract development, manufacturing, and testing from pre-clinical to commercial to accelerate your milestones and breakthrough – with one experienced partner. We offer 15+ years of leading expertise in the conjugation of drug linkers to monoclonal antibodies (mAbs) and facilities specialized for handling highly potent compounds. To fit your ADC manufacturing needs, our joint ADC offering includes a comprehensive processing portfolio from cell culture media to buffers, salts, and stabilizers and from chromatography to TFF equipment, including single-use templates.

www.sigmaaldrich.com

NJ Bio, Inc.

NJ Bio Inc. is a CRO that provides integrated chemistry and biology services to clients from the biotech and pharma sectors. Main service areas include antibody drug conjugates, nucleotide and oligonucleotide synthesis, multi-step organic synthesis, PROTAC and flow chemistry based process development.

www.njbio.com

Singzyme

Singzyme’s mission is to deliver on the promise of effective immune-therapies by developing safer and more homogenous, precision medicines for the well-being of patients worldwide. Singzyme applies its platform technology in the field of immune-therapies with a focus on the conjugation of active molecules to protein carriers, for example, but not limited to Antibody-Drug Conjugates (ADCs).

www.singzyme.com

Tubulis

Reimagining Antibody Drug Conjugates

Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibodydrug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and will collaborate with partners to usher in a new ADC era and deliver better outcomes for patients

https://tubulis.com/

WuXi XDC

WuXi XDC is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products.

www.wuxixdc.com

Program Partners

Learn More

AbTis, founded in 2016 and acquired by Dong-A ST in 2023, is a South Korean biotechnology company specializing in site-selective antibody conjugation. Its ADC linker technology, AbClick^®, allows for cost-effective ADC production with 'off-the-shelf' antibodies without altering their characteristics. Focusing on solid tumors, AbTis develops its own ADC pipelines using AbClick^® and collaborates with global partners. AbTis aims to improve patient outcomes through innovative research, positioning itself as a leader in the biopharmaceutical industry.

www.abtis.co.kr

Learn More

Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US. Abzena’s complimentary services and technologies in chemistry, biology and manufacturing, are applied to the selection, development and manufacture of better biopharmaceuticals. Abzena works with most of the top 20 biopharmaceutical companies and academic groups all over the world and is focused on enabling the development of better treatments for patients. Abzena’s technologies have enabled many of its customers to progress products through to clinical development. Abzena was created through the incorporation of Antitope, PacificGMP, PolyTherics and The Chemistry Research Solution (TCRS); all of whom now trade as Abzena.

www.abzena.com

Learn More

Learn More

AsymBio is the emerging business unit of Asymchem Group striving to become a technology-driven, fully-empowered one-stop CDMO services platform for biologic (mAb, ADC, plamsid&mRNA), offering customized services with outstanding quality and efficient performance. We have built an integrated and comprehensive CDMO service platform for ADC drugs (payload-linker, mAb, conjugation), which including but not limited to development, manufacturing, quality control and regulatory affairs. Our one-stop ADC CDMO service platform is able to efficiently empower ADCs

www.asymchem.com

Learn More

Learn More

Aureka Biotechnologies is a premier biotech startup committed to democratizing the pharmaceutical industry to defeat disease. Aureka is developing a best-in-class therapeutic discovery platform that uniquely integrates high-throughput, single-cell-based functional screening, synthetic biology-based autonomous discovery, and generative AI-based therapeutic design and multi-objective optimization. Empowered by large-scale, multi-metric data generated at an unprecedented scale and rapid reinforcement learning, Aureka’s platform can uncover therapeutic design principles and exponentially accelerate the discovery of a wide range of immunotherapeutic modalities including bispecific antibodies, ADCs, protein degraders, as well as new therapeutics for previously challenging targets and mechanisms such as GPCR.

www.aurekabio.com

Learn More

Axplora, created from the merger of Farmabios, Novasep and PharmaZell, is a leading API manufacturing partner to the world's leading pharmaceutical and biotechnology companies, delivering top quality active ingredients on time and at scale, to the highest industry standards. Axplora is dedicated to helping pharmaceutical companies make critical medicines better, faster, safely, reliably, and sustainably benefitting patients worldwide.

The group provides unique services for the development, fast-track, clinical supply and commercial cGMP manufacture of ADCs including the payload-linker and the bioconjugation, leveraging its in-house purification expertise, HPAPI culture & state-of-the art cGMP conjugation facilities. We offer a full and flexible range of ADC manufacturing services with hand-run experience on different conjugation platforms.

www.axplora.com

Learn More

Catalent Biologics provides advanced technologies and solutions for protein and gene therapy development, manufacturing and clinical supply. With technology platforms including GPEx® cell line engineering, SMARTag® bioconjugation and AAV viral vector expression combined with comprehensive analytical services and fill/finish supply, Catalent Biologics is your premier partner for clinical and commercial success.

www.biologics.catalent.com

Learn More

CATENABIO is a transformational biotech spun out of UC Berkeley, with a revolutionary and proprietary protein conjugation technology. Catena’s ground breaking approach enables never-before possible protein structures by enabling rapid, selective, scalable, and stable conjugation of proteins using only native amino acids that is capable of conjugation outside of the N- and C- termini. Catena’s key focus areas include first-in-class ‘multi payload conjugates’ called MPC®.

CatenaBio aims to disrupt the ADC market through its early pipeline of revolutionary MPC® and strategic partnerships.

www.catenabio.com

Learn More

CHO PHARMA is a glycoscience-centered biotech company that develops state-of-the-art glycoengineering technologies to create next-generation medicines. Our pioneering work has delivered CHOptimax^TM, a clinical-stage platform technology that provides a total solution for ADC development.

Using our proprietary donor substrates, CHOptimax™ enables one-step payload conjugation at the conserved Fc N-glycosylation site. Moreover, enhancements, including dual-payloads or higher DAR numbers, on such glycosite-specific ADCs can be easily achieved by CHOptimax™ as well. To creatively bring more promising medicines for more patients in need, we welcome any type of collaboration.

More info at:

www.chopharma.com

Learn More

Cytiva and Pall Life Sciences have come together to deliver the breadth, depth, and scale researchers and biopharma need to advance future therapeutics—from discovery to delivery. Together, as Cytiva, we supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™.

Visit cytiva.com to learn more.

Learn More

GeneQuantum is a global leader in the ADC field, renowned for leading the advancement of enzymatic site-specific conjugation technologies. GQ has successfully pioneered two innovative enzymatic site-specific conjugation technologies: iLDC and iGDC. These technologies serve as the foundation of our robust ADC drug development platform, covering the entire spectrum from initial design of ADC drug to seamless full-scale commercial production. Distinguishing itself from conventional ADC drugs, those fortified with GQ's technology offer a multitude of benefits including exceptional product homogeneity, elevated process quality, and enhanced metabolic stability.

http://www.genequantum.com/#/

Learn More

Glykos is a late preclinical stage biopharmaceutical company working on best-in-class ADCs with outstanding therapeutic index. Glykos has fully developed auristatin, anthracyclin and exatecan linker-payloads for ADC generation, as well as hydrophilic linker for application with novel payloads.

Glykos’ pipeline has three preclinical ADC candidates. GLK-10 is directed to HER2-expressing solid tumors, GLK-21 targets a non-disclosed melanoma antigen, and GLK-33 is an anti-CD33 auristatin ADC against AML. We welcome co-development opportunities with these and novel ADCs.

www.glykos.fi

Learn More

IntoCell is a Korea-based biotechnology company dedicated to the development and commercialisation of novel antibody drug conjugate platform technologies. The company has developed a state of the art linker technology comprising of a novel self-immolative group based on OHPAS (Ortho-Hydroxy Protected Aryl Sulfate) chemistry that works with a wide variety of phenolic and non-phenolic payloads. The OHPAS linker is designed to release phenolic payloads through intramolecular cyclization, mediated by ortho-hydroxyl group temporarily blocked by a triggering group. The technology has been extended to non-phenolics by introducing a phenolic spacer. The linker, with or without phenolic spacer, has been applied to full ADCs, which showed excellent dose dependent efficacy both in vitro and in vivo.

www.intocell.co.kr

Learn More

InxMed Co., Ltd is a China-based clinical-stage biotechnology company dedicated on developing innovative therapies to overcome treatment resistance for hard-to-treat solid tumors. IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), is able to boost efficacy of ADCs preclinically. FAK signaling has been shown to be important in pathologic fibrosis in various tissues. Overexpression of FAK is correlated with poor treatment responses and treatment resistance in many tumors. Meanwhile, one critical factor limiting ADC effectiveness is poor access to tumor cells, especially in high stroma tumors. Preclinical data demonstrated that IN10018 was able to break down the fibrotic barrier, improving penetration of large molecules including ADC. Significant synergy was observed between IN10018 and ADCs such as Enhertu and Trodelvy in stroma rich tumors including pancreatic cancer, TNBC, and ovarian cancer models. Mechanistically, IN10018 is also found to synergize with various types of ADC payloads for cancer killing and delay emerging resistance.

www.en.inxmed.com

Learn More

LIDE is an award winning preclinical oncology CRO offering traditional services like 2D and 3D in-vitro assays, 1900 in-vivo PDX models covering 50 indications, CDX models, conditionally reprogrammed cell lines, and immuno-oncology studies with syngeneic or humanized mice. We also have novel in-vivo options to validate ADCs with fresh patient samples, as well as faster studies using our proprietary MiniPDX and IO-FIVE assays

https://www.lidebiotech.com/

Learn More

Learn More

Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We perform ADC sample preparation, small scale development services, customized facility design, and superior scale up of early stage processes for late stage and commercial supply. Backed by a strong reputation for industry leading analytical capabilities and quality control, Lonza can also aide in driving quick development and improving marketability of the industry’s high potential future therapies Contact adc@lonza.com or visit

www.lonza.com

Learn More

Nerviano Medical Sciences S.r.l. (NMS) is a pioneering clinical-stage biotech company revolutionizing cancer therapy. With decades of expertise, NMS harnesses cutting-edge proprietary chemistry to craft a groundbreaking portfolio of innovative payload linkers with diversified mechanisms of actions. NMS portfolio includes optimized duocarmycin, anthracycline, and targeted payloads tailored to effectively treat diverse tumors with enhanced specificity. Utilizing a rigorous screening process, and a multifunctional approach to target selection, NMS delivers unparalleled ADC development opportunities with enhanced efficacy and safety

For more information, please visit www.nervianoms.com

Learn More

Nona Biosciences is a Boston-based biotechnology company specializing in fully human, antibody-based therapeutic discovery and development. Our proprietary Harbour Mice^® discovery platforms are fully human transgenic mice that produce either fully human conventional or Heavy Chain only Antibody (HCAb) formats. Nona’s HCAbs are the first and only clinically-validated, fully human, Heavy Chain-only Antibody on the market. Fully human antibodies from the Harbour Mice^® platforms offer multiple advantages, including reduced immunogenicity and increased efficacy, which can be further extended to other antibody-based therapeutic modalities such as multi-specifics, ADCs, CAR-based and mRNA therapeutics.

Based on the Harbour Mice^® technology and Nona's comprehensive antibody capabilities and expertise, Nona is focused on driving global inventions of transformative next-generation drugs through diversified partnership strategies that include co-discovery, asset licensing, antibody discovery, and platform licensing options. Combining Nona’s antibody discovery platforms and flexible business models, more than 70 industry and academic partners have validated Nona in over 200 projects.

We are also your trusted partner for full CMC development toward IND, and afterward from the clinic into commercial release.

For more information, follow us on LinkedIn

Learn More

OmniAb’s discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence™ (BI) of our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic® (transgenic rat) and OmniClic® (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur™ features unique structural attributes of cow antibodies for complex targets. We believe the OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms to identify fully human antibodies with superior performance and developability characteristics. These proprietary technologies are joined with and leverage OmniDeep™, which is a suite of in silico tools for therapeutic discovery and optimization that are woven throughout OmniAb’s various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology and creates opportunities in many emerging target classes. OmniAb antibodies have been leveraged across modalities, including bispecific antibodies, antibody-drug conjugates and others.

The OmniAb suite of technologies span from BI-powered repertoire generation to cutting edge antibody discovery and optimization offering a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.

For more information, please visit www.omniab.com.

Learn More

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products & services, and potent solid oral drug product. Our track record as a trusted service provider with experience across varied technologies makes us a partner of choice for innovator and generic companies worldwide.

For more information please visit: www.piramalpharmasolutions.com | Twitter | LinkedIn

Learn More

Precision AntibodyTM is a global leader in custom antibody development. Among our comprehensive services, we develop royalty-free, fully human, epitope-rich, high affinity, monoclonal therapeutic antibodies tailored to your needs in 60 days. We are recognized for delivering antibodies that work in your intended assay through strategic antigen design and screening assays. We develop anti-idiotype antibodies for PK and ADA assays and offer preclinical in vitro and in vivo assays. Contact us at: https://precisionantibody.com or orders@precisionantibody.com.

Learn More

Formed in 2015, PROVEO is now a Division of Cerbios- Pharma SA focused on complete supply chain solution for Antibody Drug Conjugates (ADCs).
Thanks to the partnership with AGC Biologics and Oncotec, PROVEO offer best-in-class solutions for the integrated development and cGMP manufacturing of recombinant proteins (incl mAbs), cytotoxic drug-linker payload, conjugation, aseptic fill and lyophilization. Strengths of the three PROVEO partners secure a seamless and low risk ADC supply chain for clinical and commercial projects.

www.proveoadc.com

Learn More

Samsung Biologics is a fully integrated CDMO partner of choice, providing highly tailored solutions to clients while meeting the evolving needs of the global healthcare industry. With proven regulatory approvals, we provide seamless offerings from cell-line development to final fill/finish at every stage for biopharmaceutical products. Our plants are cGMP compliant with a wide range of bioreactor scales to serve varying client needs and meet growing market demand. We hold a total capacity of 604KL at Bio Campus I, the world’s largest biomanufacturing site, and have announced plans to construct a fifth plant, which will be operational in 2025.

https://partner.samsungbiologics.com

Learn More

SCIEX delivers solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all. Today, as part of the Danaher family of global life science and technology innovators, we continue to pioneer robust solutions in mass spectrometry and capillary electrophoresis.

That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives.

www.sciex.com

Learn More

Shasqi's unique CAPAC® (Click Activated Protodrugs Against Cancer) platform uses Nobel Prize winning technology, click chemistry, to selectively activate high doses of cancer drugs directly at the site of the tumor, minimizing toxicity to healthy cells and potentially improving the therapeutic index by dramatically altering the exposure.

CAPAC builds on the advances achieved by antibody-drug conjugates (ADCs), changing what's possible with antigen targeted drug activation. Shasqi has developed an expansive and diverse library of antigen targeting activators and cancer therapeutic protodrugs. These two components are decoupled from each other and united at the site of the tumor via a click chemistry reaction. We are the first company to use click chemistry in humans.

Shasqi is advancing the development of new tumor targeting activators and protodrugs on an ongoing basis and is in active collaboration with partners in the biopharmaceutical industry to expand the CAPAC library of antigen targeting activators and protodrugs.

https://www.shasqi.com/

Learn More

Sony Corporation is a wholly owned subsidiary of Sony Group Corporation and is responsible for the Entertainment, Technology & Services (ET&S) business. As part of Sony’s efforts in the life science field, the KIRAVIA Backbone system was initially developed as a new dye class (KIRAVIA Dyes^TM) using a phosphate-based polymer technology. KIRAVIA Backbone has evolved into an ideal linker alternative for ADCs due to its high flexibility in design and hydrophilic characteristics. It offers easy access to next-generation ADCs such as high DAR and multi-payload ADCs.

https://www.sony.net/corporate/information/news/202305/23-0516E/

Learn More

Synaffix is a biotech company with a clinical-stage platform technology that enables best-in-class antibody-drug conjugates (ADCs), bispecific antibodies and other targeted therapeutics under a technology out-licensing business model. Synaffix was fully acquired by Lonza in June 2023. Aimed at enabling innovative medicines for patients in areas of high unmet medical need, Synaffix has forged a growing number of collaborations with top tier biotech and pharma companies by enabling best-in-class therapeutic candidates for their pipelines. Centered entirely around the antibody glycan, Synaffix has established a simple, rapidly deployable technology platform, enabling any company with an antibody to develop a proprietary, best-in-class ADC or bispecific.

GlycoConnect™ enables best-in-class therapeutic efficacy and tolerability

HydraSpace® further differentiates efficacy and tolerability versus other site-specific ADC approaches

toxSYN® linker-payloads provide multiple options to maximize efficacy in light of tumor biology

Proprietary DAR1 technology

https://synaffix.com/

Learn More

T-E Meds, Inc. founded in 2014, focuses on the research and development of a series of novel drugs based on our “T-E” technology platform. These new pharmaceuticals, containing targeting (T) and effector (E) moieties, are created by proprietary “Multi-Arm Linkers”. The drug-design platform can be employed for constructing ultra-long-acting peptide drugs, and antibody-drug conjugates (ADCs) and antibody-radionuclide conjugates (ARCs) with monospecific and bispecific antibodies.

https://www.temeds.com/

Learn More

Tempus AI, Inc. is a technology company leading the adoption of AI to advance precision medicine and patient care. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Trinity_SafeBridgeRegulatoryLifeSciencesGroup_Iron_RGB

Learn More

Veranova is a global leader in the development and manufacturing of specialist and complex active pharmaceutical ingredients for pharma and biotech customers. Veranova’s global team of highly skilled process chemists and analytical scientists possess over a decade of experience developing and scaling up processes for linking small molecule payloads to polymers in support of antibody-drug conjugates and polymer drug conjugates.

www.vernova.com

Exhibitors

Learn More

Learn More

Altruist Biologics is a fully integrated CDMO, focusing on the development and commercial manufacturing of antibodies, fusion proteins, ADCs, and other drugs. From cell line development to aseptic fill/finish, we are committed to supporting our clients develop affordable and high-quality biopharmaceuticals for the benefit of patients worldwide. We offer a total 60KL capacity at our Suzhou site, and commenced partial operations at our new Hangzhou facility with the completion of four 20KL bioreactors, the first and largest of its kind in China. The site will hold a total capacity of 172KL when it becomes fully completed in the second half of 2024. Guided by the values of “Perseverance for Altruism, Ingenuity for Sustainability,” we continuously strengthen our capabilities and quality systems in line with anticipated market and client needs to provide the most efficient and cost-effective services.

www.altruistbio.com

Learn More

Apeloa (普洛) , part of Hengdian Group (横店集团), is a top 5 pharmaceutical CDMO in China. Apeloa has been engaged in CDMO for over 20 years currently with 8 manufacturing sites and over 7,400 employees. The R&D centers are located in Boston, Shanghai, and Hengdian with a staff of over 600. The R&D capabilities include flow chemistry, synthetic biology, particle engineering, PROTAC, peptide, and ADC. Apeloa has the largest manufacturing capacity among the top 5 CDMOs in China. Apeloa has been inspected by USD FDA 18 times since 2006.

www.apeloacdmo.com

Learn More

Learn More

BASF Bioservices provides end-to-end R&D services to Life Science, Biotechnology, and BASF Group companies. Our best-in-class R&D platform includes all capabilities required for biotechnology research services and product development, from discovery and screening to large scale production of microbial fermentation products, biobased chemicals, and biocatalysts.

With over 30 years of experience and more than 200 Biotech R&D experts globally, of which 50 at our San Diego site, we enable our customers to achieve their research, development, and scale-up goals, time and time again!

Capabilities & Services include: Discovery, Engineering, Strains, Bioprocessing, Formulations and Screening

Bioservices (basf.com)

Learn More

Learn More

BOC Sciences, established in 2005 in Shirley, NY, specializes in small molecules and bioconjugates synthesis, biosynthesis, purification, characterization and validation. Our comprehensive multidisciplinary platforms empower us to deliver one stop solution for our customers, offering a wide range of in stock payloads, linkers and conjugates, as well as tailored solutions for novel structures. From laboratory to manufacturing scales, we possess robust synthesis and fermentation capabilities for payloads and linkers production.

Our Bioconjugation platform services extend beyond ADCs to encompass AOCs, PDCs, POCs, and other advanced XDC species, ensuring we stay at the forefront of cutting-edge technologies. With a commitment to excellence and innovation, BOC Sciences is your trusted partner for your XDC needs.

www.bioconjugation.bocsci.com

Learn More

Biocytogen is a biotechnology company committed to the discovery of antibody-based drugs with global partners. Biocytogen’s Project Integrum aims to discover fully human antibody-based drugs for 1000+ targets using its proprietary RenMab-based platforms. It has resulted in hits against 700+ targets, 50 asset partnerships and 42 RenMice licensing projects. Biocytogen also provides custom and off-the-shelf animal models, and preclinical research services for the discovery and evaluation of novel antibodies, ADCs, cell therapies, etc. Headquartered in Beijing, Biocytogen has branches worldwide."

www.biocytogen.com

Learn More

Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies.

Biointron holds a leading position in the antibody expression service industry. From gene sequence to purified antibodies, our production only takes 2 weeks. We have delivered tens of thousands of recombinant antibodies for more than 1,800 biotech and pharma companies worldwide. Contact us: +1(732)790-8340, or info@biointron.com. Visit our website: www.biointron.com

Learn More

Learn More

BroadPharm is a leading biotech company dedicated to meeting the needs of our customers. We specialize in the manufacturing and supply of high-purity PEG linkers, ADC linkers, click chemistry tools, drug delivery lipids, and biolabeling reagents for clients in the pharmaceutical and biotech sectors worldwide.

With our expertise in modern synthetic chemistry, innovative PEG & linker technologies, state-of-the-art equipment, and bioconjugation services, BroadPharm empowers customers to accelerate their research and development with cost-effective and efficient solutions.

www.broadpharm.com

Learn More

Buchiglas (Büchi AG) is a globally leading Swiss manufacturer of reactor systems and process equipment for the pharmaceutical industry – cGMP API synthesis from lab, through pilot to production scale. We specifically design and manufacture reactors and process equipment for HPAPI and ADC applications (incl. syntheses of cytotoxins). Our custom engineered equipment ensures the highest levels of safety, tightness, cleanability and the seamless integration into any containment solution.

www.buchiglas.com

Learn More

Established in 2006, Shanghai Haoyuan ChemExpress Co. Ltd. is located in Shanghai, China, with MedChemExpress LLC as a major overseas branch in New Jersey, USA. We have five R&D centers and manufacturing facilities, including Shanghai R&D center, Anhui HP API R&D and GMP manufacturing center, Gansu Haotian pharmaceutical API manufacturing plant, Anhui FTE service center, and Shandong non-GMP intermediate manufacturing plant.

ChemExpress focuses on the CDMO service of small molecule drug intermediates and APIs. For ADC industry, we provide payloads, linkers, toxins of many kinds, including the related intermediates. Over 500 different linkers, toxins, and drug-linker products have been made available in-stock, including but not limited to the modified analogs of auristantins (MMAE, MMAF, MMAD), doxorubicin, tululysins, campathecins (Exatecan, SN38), maytansinoids (DM1, DM2, DM4), ascidiantin (Trabectedin) and halichondrin (Eribulin). Our CDMO service covers custom synthesis (FFS, FTE), process development, scaling-up (GMP and non-GMP), process validation, CMC management, DMF registration, and IND filing.

In collaboration with Remegen, ChemExpress developed the process for MC-Val-Cit-PAB-Auristatin E to support the successful development and approval of the new ADC drug Disitamab Vedotin (Aidexi™). Our proprietary syntheses based on a series of patents (CN06380508, 2015; CN107805274A, 2017; CN111470998, 2020) have enabled the most economic synthesis of MC-Val-Cit-PAB-PNP and related intermediates, Exatecan and intermediates, as well as a variety of other drug-linkers and intermediates in large quantity.

Chemexpress has strong R&D teams, QC /QA teams, and CMC teams. Since 2020, our multiple HP API lines have provided payloads under GMP environment for the IND filing of several new ADCs in USA, Europe and China. Our mission is to become your CDMO partner of choice by providing quality products and professional services at cost tailored to your budget plan.

https://www.chemexpress.com/adc_highPotencyAPI

Learn More

Shanghai ChemPartner is a science-based, technology-driven global CRO/CDMO. ChemPartner is a research innovation engine with a broad portfolio of services spanning from discovery to development to biologics manufacturing. As part of our mission to provide the highest quality services to advance our clients’ projects, ChemPartner offers one-stop ADC/XDC R&D with clinically validated ADC services and 15+ years of experience. With our established conjugation and analytical methods and state-of-the-art instruments, we enable rapid development of customized ADCs for our international clients.

https://chempartner.com/

Learn More

Proficient in antibody biochemistry and engineering, Creative Biolabs has taken the lead in targeted immunotherapy and ADC development and established a comprehensive one-stop shop for ADC research and evaluation, covering antigen selection, antibody production and optimization, payload-linker synthesis, ADC conjugation, and extensive ADC characterization and pre-clinical evaluation. In addition, Creative Biolabs maintains a stock of custom-prepared products for quick deployment and concept validation regarding ADC R&D, containing an extensive list of linkers, payloads, payload-linker sets, and commonly used ADCs.

www.creative-biolabs.com

Learn More

Crown Bioscience, a JSR Life Sciences company, is a global Contract Research Organization (CRO) dedicated to improving human health through partnering with biotech and pharmaceutical companies that drive the discovery and development of oncology drugs.

The company offers a diverse portfolio of oncology and immuno-oncology platforms and services for preclinical and translational research, including in vivo, in vitro, and ex vivo, as well as advanced laboratory services.

Its laboratory services support the entire drug development timeline, from the discovery phase through to clinical trials, focusing on multi-omics biomarker assays and advanced bioanalytical services. Additionally, the company maintains an extensive biobank of liquid and human biospecimens, complete with clinical histories.

Crown Bioscience’s global presence extends across 12 locations in the US, Europe, and APAC and includes laboratory facilities that operate in environments accredited by the College of American Pathologists (CAP) and the International Organization for Standardization (ISO).

https://www.crownbio.com

Learn More

Learn More

Learn More

Learn More

Bruker Biosensors provides instruments and consumables for the advanced analysis of biomolecular interactions on biochips and single cells, which enable breakthroughs in drug discovery, life science research, and cell & gene therapies.

Bruker Biosensors commercializes switchSENSE® and Real-Time Interaction Cytometry (RT-IC) technologies. switchSENSE® is a unique platform technology for the analysis of molecule-molecule interactions. RT-IC is a groundbreaking technology enabling the real-time measurement of molecules binding to membrane targets on cells.

Visit dynamic-biosensors.com to learn more.

Learn More

Learn More

Learn More

GemPharmatech Co., Ltd. is a leading company in China to provide high-quality animal model resources and services for biomedical community as well as pharmaceutical companies. Based on more than 16 years’ practice in laboratory animals of the former entity, GemPharmatech has the vision and is striving to become one of the best one-stop service center for production, distribution, and phenotyping of gene-modified mouse models for partners all across the world.

www.gempharmatech.us

Learn More

Genovis empowers the biopharmaceutical and research industries by offering innovative tools that accelerate the development of novel treatments and diagnostics. Our flagship SmartEnzymes™ are designed for ease-of-use and rapid performance, optimizing both analytical and preparative workflows for complex biopharmaceuticals. In addition, our proprietary GlyCLICK^® technology enables precise, site-specific IgG conjugation, streamlining the creation of antibody-drug conjugates (ADCs) without the need for antibody engineering.

With extensive experience in supporting customers involved in ADC development and a dedicated custom conjugation service, Genovis supports scientists and researchers worldwide. Our innovative enzyme solutions and cutting-edge technologies are essential in the characterization, development, production, and quality control of biological drugs, advancing the future of healthcare.

https://www.genovis.com

Learn More

Glycogene INCis a technology-driven biotechnology company with the business spans from R&D all the way to the manufacturing stage. Using our chemo-enzymatic and fermentation technologies, Glycogene offers a broad products and services with high quality and competitively price, such as nucleosides, nucleotides, phosphoramidites and carbohydrates, especially a variety of the ADC linker products. We also provide custom synthesis services. Through collaboration and innovation, we aim to meet our customer’s evolving needs and expand our product line.

Visit https://www.glycogene.com/ to learn more.

Learn More

Learn More

Zhejiang Huida Biotech Co., LTD. is a Hangzhou China based company, subsidiary of Huadong Medicine Co., Ltd.. Huida focuses on R&D and commercial supply of high quality ADC payloads and linkers using microorganism and/or synthesis technology, such as: Exatecan mesylate (US DMF submitted with No. MF036614), DM1(US DMF submitted with No. MF037293), MMAE (US DMF to be submitted in Q2 of 2023), Ansamitocin P-3 (US DMF to be submitted as intended), Ansamitocin P-0 (US DMF to be submitted as intended), Calicheamicin (US DMF to be submitted as intended) other intermediates and derivatives.

Huida also provides customerization services with regulatory support including full quality study to the customers.

www.huidabiotech.com

Learn More

ILC Dover is a world-leader in the innovative design and production of engineered flexible protective solutions. Based in Frederica, Delaware, we serve the pharmaceutical industry with single-use flexible powder solutions that facilitate safe and reliable performance and productivity in the lab. CMOs and CDMOs choose our solutions for powder transfers and containment over rigid stainless-steel systems, for the significant advantages they bring to chemical synthesis of HPAPI and OSD processing for final drug products.

www.ilcdover.com

Learn More

Learn More

Learn More

Learn More

Since its establishment in 1987, Kyongbo Pharmaceutical has grown into one of Korea's leading API pharmaceutical companies, supplying raw materials to more than 30 countries at home and abroad. We have successfully achieved a track record in various regulatory agencies around the world, including the FDA, EDQM, PMDA, CFDA, and MFDS.
We have expanded our business into the field of ADCs, providing CDMO services. We provide integrated services for ADCs, from payloads production to linker production and conjugation development. As a trusted CDMO partner, we provide integrated CDMO services for ADCs production to meet the needs of clients.

www.kbpharma.co.kr/en/home

Learn More

MabPlex International provides one-stop, high-quality CRO/CMO solutions for biologics (mAb and ADCs) to our global clients. We are dedicated to help our clients accelerate development process and reduce manufacture costs. MabPlex has extensive experiences in manufacturing for therapeutic antibodies and antibody-drug conjugates (ADCs). Our manufacturing facilities with large-scale disposable lines and world-class instruments are operated by well-trained professionals in full compliance with U.S, European, and Chinese GMP regulations.

www.mabplex.com

Learn More

MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. MaxCyte builds best-in-class technology designed to facilitate complex engineering of a wide variety of cells and to drive the rapidly expanding cell therapy market forward. For over 20 years, MaxCyte has been a leader in developing transfection workflows and ventures beyond today’s processes to innovate tomorrow’s solutions. MaxCyte is headquartered in Rockville, Maryland’s I-270 Biotech Corridor.

www.maxcyte.com

Learn More

Medicilon is a professional pharmaceutical integrated R&D service contract research organization (CRO), providing a full range of one-stop new drug R&D services, in compliance with Chinese and international filing standards, to pharmaceutical companies and research institutions around the world. Our services cover the entire process of preclinical new drug research, including drug discovery, pharmacology research and preclinical research.

20 Years of Excellence
385+ IND Approved by FDA, NMPA, EMA, and TGA

2000+ Active Clients Worldwide
3100+ Scientists & Research Staff
84,600+ m² Lab Space

At Medicilon, we are dedicated to help our clients develop their research and discovery programs from initial idea all the way through the IND filing phase. Our services span across medicinal chemistry, biology, API, CMC, formulation, and preclinical studies. We provide flexible business models, including stand-alone Fee for Services (FFS) and fully integrated FTE services. In addition, our facilities are GLP/GMP compliant, US-FDA, China NMPA and AAALAC accredited. All study reports can be presented in SEND format, supporting dual filing of IND applications in the US, EU, and China.

For enquiries, please visit our website www.medicilon.com or email marketing@medicilon.com.

Learn More

Olon Group is a global leader in the development and production of active pharmaceutical ingredients (APIs) for CDMO and generic markets, integrating chemical synthesis and biological processes while always embracing the highest international safety, quality, and environmental standards.

With one of the longest track records of the API industry, having deep development expertise and a broad set of advanced technologies, we are the partner of choice which enables our client’s molecules to enter the market successfully

Olon has a global network of 11 manufacturing sites and 7 R&D centers across the globe. Thanks to our 2,300 employees, including 300 highly experienced and qualified R&D experts, we represent a highly innovative and reliable partner

At Olon, expertise and competent flexibility throughout the organization help build successful outcomes for our clients in custom chemical synthesis and microbial fermentation, while always maintaining the highest levels of safety, quality, and environmental compliance.

With our structured expertise in chemical synthesis and microbial biomanufacturing, we are one of the leading international players of API and HPAPI production. Our sites are equipped with multi-purpose, dedicated lines where we can produce at different levels of high containment, up to ultra-high-containment for high-potency and toxic products.
Our expertise is applied to the production of APIS for treatments used in many key therapeutic areas and for many breakthrough pharmaceutical products. We are leaders in the production of retinoids, antineoplastic, cardiovascular and metabolic diseases compounds, antibiotics and antivirals.

www.olonspa.com

Learn More

Learn More

Reaction Biology is a global contract research organization (CRO) that supports preclinical drug discovery with broad capabilities including protein and peptide production, over 2,000 biochemical and cell-based assays, biophysical testing, safety and toxicology, in vivo pharmacology models, and immuno-oncology services. Reaction also provides Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) analytical and functional bioassays for testing potency, efficacy, and safety of large biological molecules.

https://www.reactionbiology.com/

Learn More

Learn More

Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO), specialising in complex and hazardous science. Our dedicated bioconjugation and ADC facility in the UK supports customer’s projects from development to preclinical and clinical manufacture.

This specialised team is supported by high potency small molecule experts at our Wisconsin, US site providing integrated ADC services, including toxin linker manufacturing.

Sterling has six facilities across the UK, USA and Europe, employing more than 1,350 people.

www.sterlingpharmasolutions.com

Learn More

Symbiosis Pharmaceutical Services Ltd, licensed by the MHRA and inspected by the FDA, is a world-class fill/finish business that specializes in the GMP manufacture of sterile pharmaceuticals for clinical trials and low-volume commercial supply.

We always aim to exceed our clients' expectations in terms of responsiveness and lead times, customer service and accurate costing. Our team can handle biologics, proteins, peptides, small molecules, highly potent API's, plasmids, ATMPs and viral vectors for gene therapy.

www.symbiosis-pharma.com/services/

Learn More

Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global biopharma, nutrition, animal health, consumer goods, and specialty chemical sectors. With 6000+ world-class scientists and 2.2 Mn sq. ft specialist facilities, Syngene offers skills and capacity to improve time-to-market and lower the cost of innovation.

www.syngeneintl.com

Learn More

Learn More

Vivia has developed accurate assays for ADC agents specifically designed to characterize the ex vivo pharmacological profile in real patient samples, preserving native microenvironments. Our assays comply with FDA suggestions for IND filing. Vivia also offers specialized ADC toxicity assays that can enhance your research. We can measure hematotoxicity on myeloid progenitors and selectivity among cell types present directly in normal bone marrow samples, maintaining patient plasma for accurate in vivo-like conditions.

www.viviabiotech.com

Learn More

Wheeler Bio is a biomanufacturing pioneer founded by industry experts and strategic investors who believe a different CDMO model is needed for innovators to bring new therapeutic leads to the clinic faster, without the risk and cost associated with traditional outsourcing models. Wheeler’s pioneering, highly-accessible, open-source development platform – Portable CMC® – delivers speed to clinic and uniquely-affordable workflows by integrating discovery CROs and CDMOs. By overlapping with the discovery workflow, Portable CMC® reduces timelines and regulatory risks through the introduction of QbD principles earlier in the drug development cycle, increasing the opportunity for clinical success.

https://wheelerbio.com/

Learn More

Event Partners

Learn More

BioReinno is a biotech company focused on driving the development of next-generation ADC drugs through the innovation of ADC underlying technologies. We have built four leading ADC technology platforms: chemical site-specific conjugation technology platform MCLICK, novel camptothecin LD platform with tunable release kinetics RACT, ultra-low DAR value ADC technology platform UDAC, and dual-payload ADC technology platform DPAC. The single or combined application of these innovative technologies can empower ADC innovation in at least the following aspects: the fine adjustment and uniformity improvement of ADC DAR value(DAR1/DAR2/DAR3/DAR4/DAR6), broadening the therapeutic window of camptothecin ADC, the development of ultra-low DAR value ADC and AOC, and the proportional adjustment and development of dual-payload ADC. We look forward to working with Biopharma, Biotech, CRO and CDMO around the world to accelerate the advancement of ADC drugs.

Learn More

CARBOGEN AMCIS providea drug development and commercialisation services to the pharmaceutical and biopharmaceutical industries, at all stages of drug development. Our capabilities span from contract chemical process research and development to the supply of Active Pharmaceutical Ingredients (APIs) - as well as drug products for preclinical studies, clinical trials and commercial use. Besides being a service provider we also offer high quality Cholesterol and Vitamin D analog products produced at our facility in The Netherlands. These products are used in a variety of markets around the globe.

Our focus is to help customers create a better world by becoming the partner of choice for development and manufacture. The guiding principles for our service are our passion for great science supported by timely communication and backed by our total commitment to YOUR project.

We forge close collaboration and open communication with our customers which ensures we work effectively as a team, meeting (if not exceeding) our customers' expectations. We aim to manufacture pharmaceutical ingredients at the highest standard of GMP whilst protecting the environment.

We are a partner you can trust and we look forward to helping you move your project faster to the market.

www.carbogen-amcis.com

Learn More

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies, and clinical trials.

www.foundationmedicine.com/info/biopharma-overview

Learn More

Learn More

At Simtra, we’re made for this. With 65+ years of sterile injectable manufacturing experience, we bring precision and transparency to every step of the production process, from product development through commercial fill and finish. As a premier independent CDMO, we partner with pharmaceutical and biotech companies to help them realize their commercialization objectives for sterile injectables.

Whether you are looking to launch your innovation globally, improve your formulation, or proactively mitigate risk, Simtra can help you deliver on your commitments to patients.

www.simtra.com

Learn More

2024 EVENT GUIDE

PARTNER

Save the Date!
November 3 - 6, 2025
Sign Up for Updates

2024 PARTNERS

Lead Partner

BSP Pharmaceuticals

Senior Partners

Ambrx - Johnson & Johnson

Ajinomoto BioPharma Services

MilliporeSigma

NJ Bio, Inc.

Singzyme

Tubulis

WuXi XDC

Program Partners

Exhibitors

Event Partners

OUR CONTACT DETAILS

JOIN OUR TEAM

JOIN OUR ONLINE COMMUNITY

ABOUT US

SEARCH

EXPLORE OUR PRODUCTS

Save the Date!November 3 - 6, 2025Sign Up for Updates

2024 PARTNERS

Lead Partner

BSP Pharmaceuticals

Senior Partners

Ambrx - Johnson & Johnson

Ajinomoto BioPharma Services

MilliporeSigma

NJ Bio, Inc.

Singzyme

Tubulis

WuXi XDC

Program Partners

Exhibitors

Event Partners

OUR CONTACT DETAILS

JOIN OUR TEAM

JOIN OUR ONLINE COMMUNITY

ABOUT US

SEARCH

EXPLORE OUR PRODUCTS

Save the Date!
November 3 - 6, 2025
Sign Up for Updates